Neurological disorders caused by recreational use of nitrous oxide—a retrospective study from a German metropolitan area and review of the literature
-
Published:2025-05-04
Issue:1
Volume:7
Page:
-
ISSN:2524-3489
-
Container-title:Neurological Research and Practice
-
language:en
-
Short-container-title:Neurol. Res. Pract.
Author:
Tshagharyan Asya, You Se-Jong, Grefkes Christian, Hattingen Elke, Steinbach Joachim P., Zeiner Pia S., Hildner Marcel, Divé IrisORCID
Abstract
Abstract
Background
The recreational use of nitrous oxide (N2O) has seen a worldwide rise in the recent years, resulting in an increased incidence of neurological complications due to N2O-induced functional vitamin B12 deficiency. Here, we report on a cohort of patients admitted to a tertiary care center with neurological symptoms in the context of recreational N2O use between 2020 and 2024.
Methods
We screened the database of the University Hospital Frankfurt for patients ≥ 18 years of age who presented with neurological deficits and a history of N2O consumption between January 2020 and December 2024. We analyzed the spectrum of neurological deficits as well as radiological and laboratory findings.
Results
We identified a total of 20 patients, 16 males and 4 females, with a median age of 21 years. We found a steady increase in the number of cases, with no cases in 2020 and 2021 and a definite peak in 2024. The mean daily N2O consumption was 2500 g. All patients reported sensory deficits; 85% had gait disturbances and 70% had motor deficits. Less frequent symptoms included pain, bladder or bowel dysfunction, fatigue and spasticity. The median score on the modified Rankin scale (mRS) was 2, with some patients being wheelchair-bound. The most frequently observed lesion pattern was combined myelo-polyneuropathy. T2-hyperintense myelon lesions were observed in 11 of 15 patients (73.3%). Surprisingly, laboratory work-up revealed normal vitamin B12 levels in nearly all patients (95%), whereas homocysteine and methylmalonic acid levels were prominently elevated in all patients (100%). In addition, 13 patients (65%) presented with hematological abnormalities. All of the patients who presented for follow-up (20%) reported continued use of N2O. There was no neurological improvement in any of these cases.
Conclusions
Our study confirms that the increasing incidence of N2O-induced neurotoxicity reported in other countries can also be observed in Germany. Therefore, it underlines the relevance of the current debate on health policies. In addition, our study highlights the pitfalls of vitamin B12 laboratory testing and emphasizes the need to address substance addiction in treatment.
Funder
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Back, S., Kroon, E., Colyer-Patel, K., & Cousijn, J. (2024). Does nitrous oxide addiction exist? An evaluation of the evidence for the presence and prevalence of substance use disorder symptoms in recreational nitrous oxide users. Addiction (Abingdon, England), 119(4), 609–618. https://doi.org/10.1111/add.16380 2. Chanarin, I. (1982). The effects of nitrous oxide on cobalamins, folates, and on related events. Critical Reviews in Toxicology, 10(3), 179–213. https://doi.org/10.3109/10408448209037455 3. Cruz, E. S., Fortanier, E., Hilezian, F., Maarouf, A., Boutière, C., Demortière, S., Rico, A., Delmont, E., Pelletier, J., Attarian, S., & Audoin, B. (2024). Factors affecting the topography of nitrous oxide-induced neurological complications. European Journal of Neurology, 31(7), e16291. https://doi.org/10.1111/ene.16291 4. Dawudi, Y., Azoyan, L., Broucker, T. D. E., Gendre, T., Miloudi, A., Echaniz-Laguna, A., Mazoyer, J., Zanin, A., Kubis, N., Dubessy, A.-L., Gorza, L., Ben Nasr, H., Caré, W., d’Izarny-Gargas, T., Formoso, A., Vilcu, A.-M., & Bonnan, M. (2024). Marked increase in severe neurological disorders after nitrous oxide abuse: A retrospective study in the Greater Paris area. Journal of Neurology, 271(6), 3340–3346. https://doi.org/10.1007/s00415-024-12264-w 5. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2024: Trends and Developments. https://www.euda.europa.eu/publications/european-drug-report/2024_en
|
|